# Inovio Pharmaceuticals, Inc.: overview INO · Nasdaq · CIK 1055726 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ino.md) · [Financials](/companies/ino/financials.md) · [Filings](/companies/ino/filings.md) · [Insiders](/companies/ino/insiders.md) Latest reported revenue: [$0](/filings/0001055726-26-000023.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 12, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001055726-26-000023). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001055726-25-000063.md) | [0.1 d](/filings/0001055726-26-000008.md) | [0.1](/filings/0001055726-26-000018.md) | [0.0](/filings/0001055726-26-000023.md) | [0.0](/filings/0001055726-25-000063.md) | [0.0 d](/filings/0001055726-26-000008.md) | [0.0](/filings/0001055726-26-000018.md) | [0.0](/filings/0001055726-26-000023.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | [(17410.8%) d](/filings/0001055726-26-000008.md) | [(38337.0%)](/filings/0001055726-26-000018.md) | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | [(16566.4%) d](/filings/0001055726-26-000008.md) | [(30140.5%)](/filings/0001055726-26-000023.md) | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.89)](/filings/0001055726-25-000063.md) | not reported | [(0.51)](/filings/0001055726-26-000018.md) | [(0.61)](/filings/0001055726-26-000023.md) | [(0.87)](/filings/0001055726-25-000063.md) | not reported | [(0.28)](/filings/0001055726-26-000018.md) | [(0.07)](/filings/0001055726-26-000023.md) | | Free cash flow | $m | [(27.4) d](/filings/0001055726-25-000063.md) | [(19.7) d](/filings/0001055726-26-000008.md) | [(26.9)](/filings/0001055726-26-000018.md) | [(20.8) d](/filings/0001055726-26-000023.md) | [(21.6) d](/filings/0001055726-25-000063.md) | [(19.5) d](/filings/0001055726-26-000008.md) | [(21.6)](/filings/0001055726-26-000018.md) | [(18.0) d](/filings/0001055726-26-000023.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1.8](/filings/0001055726-24-000011.md) | [10.3](/filings/0001055726-24-000011.md) | [0.8](/filings/0001055726-25-000012.md) | [0.2](/filings/0001055726-26-000008.md) | [0.1](/filings/0001055726-26-000008.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(16972.3%)](/filings/0001055726-24-000011.md) | [(2607.4%)](/filings/0001055726-24-000011.md) | [(17300.3%)](/filings/0001055726-25-000012.md) | [(51616.9%)](/filings/0001055726-26-000008.md) | [(132871.3%)](/filings/0001055726-26-000008.md) | | Net margin | % | [(17109.9%)](/filings/0001055726-24-000011.md) | [(2726.7%)](/filings/0001055726-24-000011.md) | [(16239.9%)](/filings/0001055726-25-000012.md) | [(49254.3%)](/filings/0001055726-26-000008.md) | [(130000.0%)](/filings/0001055726-26-000008.md) | | Diluted EPS | $ per share | [(17.45)](/filings/0001055726-24-000011.md) | [(14.07)](/filings/0001055726-24-000011.md) | [(6.09)](/filings/0001055726-25-000012.md) | [(3.95)](/filings/0001055726-26-000008.md) | [(1.81)](/filings/0001055726-26-000008.md) | | Free cash flow | $m | [(217)](/filings/0001055726-24-000011.md) | [(217)](/filings/0001055726-24-000011.md) | [(125)](/filings/0001055726-25-000012.md) | [(105)](/filings/0001055726-26-000008.md) | [(88.9)](/filings/0001055726-26-000008.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ino/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $9.3m | 8,454,797 | | Reduced −884,817 | | [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $5.8m | 3,308,406 | | Not compared | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $5.7m | 5,171,053 | | Not compared | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $4.0m | 3,650,562 | | Added +749,354 | | [Boxer Capital Management, LLC](/funds/2018299.md) | 2026-06-30 | $3.1m | 2,844,994 | | Added +474,872 | | [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $2.4m | 2,143,910 | | Added +673,802 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $1.7m | 1,520,400 | Call | Added +1,251,700 | | [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $1.5m | 1,351,656 | | Reduced −861,163 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $1.4m | 1,239,778 | | Added +849,394 | | [Eversept Partners, LP](/funds/1697013.md) | 2026-06-30 | $1.1m | 1,035,360 | | Unchanged | ## Recent filings [All 948 filings](/companies/ino/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-06 | 20:06 ET | [8-K](/filings/0001193125-26-415555.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-26-415555 | | 2026-08-12 | 20:07 ET | [8-K](/filings/0001055726-26-000024.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001055726-26-000024 | | 2026-08-12 | 20:00 ET | [10-Q](/filings/0001055726-26-000023.md) | Quarterly report, period 2026-06-30 | 0001055726-26-000023 | | 2026-07-31 | 11:23 ET | [8-K](/filings/0001193125-26-326785.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-326785 | | 2026-07-29 | 20:03 ET | [8-K](/filings/0001193125-26-323628.md) | 2.02 Results of operations | 0001193125-26-323628 | | 2026-05-20 | 20:01 ET | [8-K](/filings/0001193125-26-232524.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-232524 | | 2026-05-13 | 20:07 ET | [8-K](/filings/0001055726-26-000019.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001055726-26-000019 | | 2026-05-13 | 20:01 ET | [10-Q](/filings/0001055726-26-000018.md) | Quarterly report, period 2026-03-31 | 0001055726-26-000018 | | 2026-04-07 | 20:11 ET | [DEF 14A](/filings/0001055726-26-000011.md) | Proxy statement, period 2026-05-20 | 0001055726-26-000011 | | 2026-04-06 | 11:03 ET | [8-K](/filings/0001193125-26-142885.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-142885 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001055726-26-000008.md), filed Mar 12, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/d6d85f85-bae6-4f67-adf1-94797eed1789) ## About the filer - CIK: 1055726 - Tickers: INO - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:31 ET. No prices; not investment advice.